Author:
Yin Ting,Liu Yewei,Peeters Ronald,Feng Yuanbo,Yu Jie,Himmelreich Uwe,Oyen Raymond,Ni Yicheng
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Chase DM, Chaplin DJ, Monk BJ (2017) The development and use of vascular targeted therapy in ovarian cancer. Gynecol Oncol 145: 393–406.
2. Chen F, Sun X, De Keyzer F, Yu J, Peeters R, Coudyzer W, Vandecaveye V, Landuyt W, Bosmans H, Van Hecke P, Marchal G, Ni Y (2006) Liver tumor model with implanted rhabdomyosarcoma in rats: MR imaging, microangiography, and histopathologic analysis. Radiology 239: 554–562.
3. Colliez F, Fruytier AC, Magat J, Neveu MA, Cani PD, Gallez B, Jordan BF (2016) Monitoring Combretastatin A4-induced tumor hypoxia and hemodynamic changes using endogenous MR contrast and DCE-MRI. Magn Reson Med 75: 866–872.
4. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829–1834.
5. Fruytier A-C, Magat J, Neveu M-A, Karroum O, Bouzin C, Feron O, Jordan B, Cron GO, Gallez B (2014) Dynamic contrast-enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4. NMR Biomed 27: 1403–1412.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献